AU
UK
CA
NZ
IND
US
Biotech stocks made headlines on Thursday, September 25, 2025, with standout performances driven by unique company developments and promising clinical progress. Despite a challenging market environment, PepGen Inc., HeartSciences Inc., and Jasper Therapeutics delivered remarkable gains, fueled by innovation, strategic pivots, and investor optimism. …
Evaxion A/S (NASDAQ:EVAX), a clinical-stage TechBio company focused on AI-Immunology™ powered vaccines, announced that MSD (Merck & Co., Inc.) has exercised its option to license the vaccine candidate EVX-B3. As part of the agreement, Evaxion receives a $7.5 million cash payment and is eligible …
JPMorgan Chase & Co. increased its target price for Roivant Sciences Ltd. (NASDAQ:ROIV) from USD 16.00 to USD 20.00 in a research note issued on Thursday, according to Benzinga. The brokerage maintained an “overweight” rating, citing potential upside of 32.98% based on the stock’s …
Harrow (NASDAQ:HROW) operates in the healthcare sector. It provides laboratory testing, clinical services, and related solutions. The company focuses on diagnostics, personalized medicine, and laboratory services across several therapeutic areas.
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (NASDAQ: SNY | EURONEXT: SAN) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Dupixent® (dupilumab) in the European Union for the treatment of …
TransMedics Group, Inc. (Nasdaq:TMDX), a medical technology company focused on organ transplant therapy, announced a strategic collaboration with Mercedes-Benz Group AG to introduce a fleet of purpose-built Mercedes-Benz V-Class vehicles dedicated to organ transportation across Italy. This initiative aligns with TransMedics’ plan to replicate …
Skye Bioscience, Inc. (Nasdaq:SKYE), a clinical-stage biotechnology company developing therapies for obesity and metabolic health disorders, presented results from its Phase 1b study of nimacimab at the European Association for the Study of Diabetes (EASD) Annual Meeting. The trial evaluated nimacimab in subjects with …
CytomX Therapeutics, Inc. (NASDAQ:CTMX), an oncology-focused biopharmaceutical company, received an upgrade from Barclays research analysts, moving its rating to "strong-buy,". This marks the latest in a series of analyst actions on the stock.
Biogen Inc. (Nasdaq: BIIB) announced that the European Commission (EC) has granted marketing authorization for ZURZUVAE® (zuranolone) for the treatment of post-partum depression (PPD) in adults following childbirth. The decision makes ZURZUVAE the first and only treatment specifically indicated for PPD in the European …
NovoCure Limited (NASDAQ: NVCR),a medical equipment company specializing in tumor treating fields (TTFields) devices for solid tumor cancers, currently holds a consensus analyst rating of"Moderate Buy,"according to MarketBeat Ratings. This consensus is derived from seven analysts covering the stock, with four recommending a buy …
Please wait processing your request...